PubMed Health⌕ Search

Biomedical subjects

J Hlávková

Publications and source records attributed to J Hlávková.

11 recordsLinked to original sources
PubMed1989

Complex biochemical analysis of human breast tumor tissue.

The quantitative biochemical analysis of tissue specimens from 76 human breast carcinomas consisted of examination for cytosolic estrogen receptors (cER), nuclear estrogen receptors (nER), progesterone receptors (PgR), 1,25-dihydroxycholecalciferol receptors (DR), carcinoembryonic antigen (CEA), alpha-lactalbumin (aLA), and gamma-glutamyl transferase (gGT). The highest incidence was found in CEA (76%), DR (70%), and aLA (62%). There was a high percentage of tumors containing only DR, in contrast to the tumors containing only cER or PgR. The simultaneous occurrence of DR and CEA was considerably high (61%). No statistically significant differences were observed in these biochemical parameters in relation to the grade of differentiation of the tumors. The values of aLA in tumors that invaded lymphatic or blood vessels were lower as compared to those tumors that invaded adipose or connective tissues. The level of statistical significance of this difference was close to 5%, the differences in other parameters were statistically insignificant. For prognosis assessed at the time of surgery, after a 2-3-year follow-up of 36 patients the level of gGT in the tumor seems to be the most promising prognostic factor. The values of gGT were significantly lower in those patients whose tumors were in progression during this time. The significance of nER and aLA was also taken into consideration.

Breast Neoplasms↗
PubMed1986

A, B, O blood groups and the course of breast cancer disease.

551 clinical records of breast cancer patients were retrospectively analysed. Several parameters have been examined: age at presentation, distribution of stages at the time of diagnosis, incidence of any progression and "progression- free" interval after primary treatment, incidence of distant dissemination and distant meta- free interval, cancer mortality, time of survival from presentation and time of survival from detection of distant metastases (stage at presentation being taken into account in all evaluations). The results within various ABO blood groups were mutually compared. There were no substantial differences in these parameters within different blood groups. Immunological point of view, dealing with possible loss or modifications of ABH (O) isoantigens on tumour cells and the immune response to these alien antigens, is discussed.

ABO Blood-Group System↗
PubMed1985

Course of breast cancer disease and ABO blood groups.

The clinical records of 551 breast cancer patients were retrospectively analysed. Several parameters have been examined: age at presentation, distribution of stages at the time of diagnosis, incidence of any progression and "progression-free" interval after primary treatment, incidence of distant dissemination and distant metastasis-free interval, cancer mortality, time of survival from presentation and time of survival from detection of distant metastases (stage at presentation being taken into account in all evaluations). The results within various ABO blood groups were compared. There were no substantial differences in these parameters within different blood groups. The possible modifications of ABH (O) isoantigens on tumour cells and the immune response to these alien antigens is discussed.

ABO Blood-Group System↗
PubMed1985

DNCB and PPD skin tests and prognosis in 152 patients with breast cancer. A prospective 2-year follow-up.

The relationship of pretreatment immunologic status in terms of skin tests to prognosis within stages was studied in 152 breast cancer patients. DNCB and PPD testing was used. As for DNCB, no relationship was found at early stages of the disease. In locoregionally advanced disease, patients with stronger test grades had longer disease-free intervals. In case of distant dissemination significant difference in reactivity with respect to survival was found: short survivors were more frequently nonresponders or mild responders. Anergy was, however, more frequent in patients with general ill health and therefore this test does not provide an important additional prognostic information as compared to that given by conventional clinical findings. As for PPD, no relationship between reactivity to this antigen and prognosis at any stage of the disease was found.

Breast Neoplasms↗
PubMed1984

Three-year follow-up of carcinoembryonal antigen levels in the serum of patients with breast cancer.

The levels of carcinoembryonal antigen (CEA) were followed up for three years in 66 patients with breast cancer. In the group of patients treated surgically (N = 36, T1-2, NO-2, MO) the values of CEA were in agreement with the clinical course in 97% of the patients (35 out of 36 patients). Recurrence and/or dissemination of the disease were signalled by a rise in the serum CEA level to more than 15 micrograms/1 out four out of five patients more than 3-10 months before clinical manifestation. In the group of patients without surgery, who were treated by radiation and/or chemotherapy (N = 30, T2-4, NO-3, MO) the serum CEA values were in agreement with the clinical course in 71% of the patients (20/28). Within three years recurrence and/or dissemination were detected in 57% patients (16/28), ten patients died (10/30--two of them were not evaluated). The recurrence or dissemination were signalled in seven out of 16 patients (44%) more than 4-14 months before clinical detection, in three patients (19%) the rise was detected simultaneously with the clinical finding (examinations at 3-4 months intervals), and in 6 patients (38%) the CEA level was at variance with the clinical finding.

Breast Neoplasms↗
PubMed1984

No difference in delayed hypersensitivity between breast and cervical carcinomas.

DNCB and PPD skin testing was performed in 130 breast and 110 cervical cancer patients. BATES' instruction with a plea for uniformity was used [1]. Patients were tested while being diagnosed and prior to the treatment. No significant differences either in the frequency of a reactivity or grade of response in corresponding stages of breast and cervical cancer were found.

Breast Neoplasms↗
PubMed1983

Leukocyte adherence inhibition responses obtained with various tumor extracts in breast cancer patients.

Leukocyte adherence inhibition (LAI) assay was employed to detect cell-mediated immune response in breast cancer patients of clinical stages I and II. Twenty-one breast cancer extracts were screened in 232 breast cancer patients and 343 healthy persons. The activity of individual extracts differed remarkably. Overall, LAI response was 58.6% (136/232) correct and 18.9% (65/343) false positive. Fifteen extracts were not suitable from the clinical point of view. Only two extracts gave a constantly high rate of tumor-specific LAI-positive values in breast cancer patients, ie, 83.3% (25/30) and low percentage of false positive results in controls, ie, 4% (2/50). A further study dealt with the possible relation between the activity of extracts (expressed in percentage of positive LAI results in the tumor group) and histology of primary tumor of patients whose tumor tissue was used for extraction. This relationship could not be proven statistically. We investigated also whether the percentage of correct LAI responses in breast cancer patients could be affected by histological agreement or disagreement (grading and node involvement) between primary tumor of extract donor and primary tumor of patients tested. No significant relationship was found in this respect.

Adult↗
PubMed1983

DNCB and PPD skin testing in breast cancer.

DNCB and PPD skin testing was performed in 152 breast cancer patients. Bates' instruction with a plea for uniformity was used (Cancer, 43, 1979, 2306). Majority of patients were tested while being diagnosed and prior to the treatment. There were no differences in the reactivity within early operable breast cancer patients (Stage I and II) with respect to nodal involvement. Patients with N1 reacted in the same manner as those with N0. The reactivity of patients with locoregionally advanced disease (Stage III) was similar to that of Stage I and II patients. Significantly lower responsiveness was found in Stage IV patients, the depressed response to DNCB being more pronounced than to PPD.

Breast Neoplasms↗